Lyell Immunopharma Inc
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 251
- Market Cap
- $373.7M
- Website
- http://www.lyell.com
A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
- Conditions
- Lupus NephritisSystemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Lyell Immunopharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06153095
- Locations
- 🇺🇸
University of California, Los Angeles (UCLA) Medical Center, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
A Biomarker Screening Protocol for Participants With Solid Tumors
- Conditions
- Triple Negative Breast CancerNon-small Cell Lung CancerNon Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNon-Small Cell Carcinoma of Lung, TNM Stage 4Advanced Breast CancerAdvanced Lung CarcinomaNSCLCNSCLC, RecurrentNSCLC Stage IV
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Lyell Immunopharma, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT05891197
- Locations
- 🇺🇸
Accellacare, Rocky Mount, North Carolina, United States
Study of LYL314 in Aggressive Large B-Cell Lymphoma
- Conditions
- Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon-Hodgkin LymphomaLarge B-cell Lymphoma
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Lyell Immunopharma, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT05826535
- Locations
- 🇺🇸
Corewell Health, Grand Rapids, Michigan, United States
🇺🇸University of California-Irvine Medical Center, Irvine, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
A Study to Investigate LYL845 in Adults With Solid Tumors
- Conditions
- MelanomaNon-small Cell Lung CancerColorectal Cancer
- Interventions
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Lyell Immunopharma, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT05573035
- Locations
- 🇺🇸
UC Davis Coomprehensive Cancer Center, Sacramento, California, United States
🇺🇸UCLA Medical Center, Santa Monica, California, United States
🇺🇸Stanford University, Stanford, California, United States
A Study to Investigate LYL797 in Adults With Solid Tumors
- Conditions
- Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerNon-small Cell Lung CancerNon Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNon-Small Cell Carcinoma of Lung, TNM Stage 4Advanced Breast CancerAdvanced Lung CarcinomaNSCLCNSCLC, Recurrent
- Interventions
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Lyell Immunopharma, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT05274451
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of California, Los Angeles, Santa Monica, California, United States
🇺🇸Yale New Haven Hospital, New Haven, Connecticut, United States